Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The trial demonstrated that Foundayo significantly outperformed oral semaglutide and dapagliflozin in managing type 2 diabetes, showing superior glycemic control and weight reduction
Data availability The data that support the findings of this study were obtained from the TriNetX Research Network, a federated, multi-institutional clinical research platform that provides access to de-identified electronic health record data
doi: 10.1016/j.clinme.2024.100030 [PubMed] 39407841 Scafetta T, Kovacs O, Milani GP, Bronz G, Lava SAG, Betti C, Vanoni F, Bianchetti MG, Far PB, Camozzi P
Response is individual, and we don't guarantee outcomes
US$ 23.50
US$ 22.50
)
US$ 22.62
